Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 27;9(4):920.
doi: 10.3390/jcm9040920.

The Public Health Burden of Cardiomyopathies: Insights from a Nationwide Inpatient Study

Simon Lannou  1 , Nicolas Mansencal  1   2 , Cécile Couchoud  3 , Mathilde Lassalle  3 , Olivier Dubourg  1   2 , Bénédicte Stengel  2 , Christian Jacquelinet  2   3 , Philippe Charron  1   4   5
Affiliations

The Public Health Burden of Cardiomyopathies: Insights from a Nationwide Inpatient Study

Simon Lannou et al. J Clin Med. .

Abstract

Cardiomyopathies are responsible for heart failure and sudden cardiac death, but epidemiological data are scarce and the public health burden may be underestimated. We studied aggregating data from all public or private hospitals in France. Patients were categorized from relevant ICD-10 codes into dilated, hypertrophic, restrictive, or other cardiomyopathies (DCM, HCM, RCM, or OCM, respectively). Between 2008 and 2015, a total of 326,461 distinct patients had cardiomyopathy-related hospitalizations. The hospital-based prevalence of cardiomyopathy was 809 per million inhabitants (PMI) per year, including 428 PMI for DCM, 101 PMI for HCM, 26 PMI for RCM, and 253 PMI for OCM. Patients with cardiomyopathies accounted for 51% of all heart transplants, 33% of defibrillator implantations, 38% of mechanical circulatory supports, and 11.3% of hospitalizations for heart failure. In patients less than 40 years of age, these figures were 71%, 51%, 63%, and 23%, respectively. Over 2008-2015 and considering all cardiomyopathies, there was a significant increase for heart transplant (average annual percentage change, AAPC: +3.86%, p = 0.0015) and for defibrillator implantation (AAPC: +6.98%, p < 0.0001), and a significant decrease of in-hospital mortality (AAPC: -4.7%, p = 0.0002). This nationwide study shows that cardiomyopathies constitute an important cause of hospitalization, with increasing invasive therapeutic procedures and decreasing mortality.

Keywords: cardiomyopathy; defibrillator; epidemiology; heart transplant; hospitalization; prevalence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest in relation to the reported research results. Other authors declare no competing interests. The funders had no role in the design, execution, interpretation, or writing of the study.

Figures

Figure 1
Figure 1
Temporal variations of inpatient prevalence of cardiomyopathy patients with at least one clinical event or procedure from 2008 to 2015: A. Heart transplants; B. Defibrillator implantations; C. Heart failure; D. In-hospital mortality. PMI: Per million inhabitants.
Figure 2
Figure 2
Proportion of patients with cardiomyopathies among all patients hospitalized for at least one major cardiovascular event or invasive therapeutic procedure in 2015. A. Proportions in the total population. B. Proportion in the subgroup of patients less than 40 years of age. Cardiac arrest: includes codes for sudden death, cardiac arrest, and aborted cardiac arrest.
See this image and copyright information in PMC

References

    1. Elliott P., Andersson B., Arbustini E., Bilinska Z., Cecchi F., Charron P., Dubourg O., Kühl U., Maisch B., McKenna W.J., et al. Classification of the cardiomyopathies: A position statement from the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur. Heart J. 2008;29:270–276. doi: 10.1093/eurheartj/ehm342. - DOI - PubMed
    1. Maron B.J., Towbin J.A., Thiene G., Antzelevitch C., Corrado D., Arnett D., Moss A.J., Seidman C.E., Young J.B. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee. Circulation. 2006;113:1807–1816. doi: 10.1161/CIRCULATIONAHA.106.174287. - DOI - PubMed
    1. Pinto Y.M., Elliott P.M., Arbustini E., Adler Y., Anastasakis A., Böhm M., Duboc D., Gimeno J., de Groote P., Imazio M., et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases. Eur. Heart J. 2016;37:1850–1858. doi: 10.1093/eurheartj/ehv727. - DOI - PubMed
    1. Miles C., Fanton Z., Tome M., Behr E.R. Inherited cardiomyopathies. BMJ. 2019;365:l1570. doi: 10.1136/bmj.l1570. - DOI - PubMed
    1. Weintraub R.G., Semsarian C., Macdonald P. Dilated cardiomyopathy. Lancet. 2017;390:400–404. doi: 10.1016/S0140-6736(16)31713-5. - DOI - PubMed

LinkOut - more resources